🚀 VC round data is live in beta, check it out!
4D Molecular Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for 4D Molecular Therapeutics and similar public comparables like AIM Vaccine, Synmosa Biopharma, GC Biopharma, Aquestive Therapeutics and more.
4D Molecular Therapeutics Overview
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Founded
2015
HQ
Employees
227
Website
Sectors
Financials (LTM)
EV
$210M
4D Molecular Therapeutics Financials
4D Molecular Therapeutics reported last 12-month revenue of $69M and negative EBITDA of ($180M).
In the same LTM period, 4D Molecular Therapeutics generated $69M in gross profit, ($180M) in EBITDA losses, and had net loss of ($163M).
Revenue (LTM)
4D Molecular Therapeutics P&L
In the most recent fiscal year, 4D Molecular Therapeutics reported revenue of $37K and EBITDA of ($181M).
4D Molecular Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $69M | XXX | $37K | XXX | XXX | XXX |
| Gross Profit | $69M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($180M) | XXX | ($181M) | XXX | XXX | XXX |
| EBITDA Margin | (261%) | XXX | (489557%) | XXX | XXX | XXX |
| EBIT Margin | (267%) | XXX | (507678%) | XXX | XXX | XXX |
| Net Profit | ($163M) | XXX | ($161M) | XXX | XXX | XXX |
| Net Margin | (237%) | XXX | (434778%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
4D Molecular Therapeutics Stock Performance
4D Molecular Therapeutics has current market cap of $493M, and enterprise value of $210M.
Market Cap Evolution
4D Molecular Therapeutics' stock price is $9.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $210M | $493M | 0.0% | XXX | XXX | XXX | $-3.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial4D Molecular Therapeutics Valuation Multiples
4D Molecular Therapeutics trades at 3.1x EV/Revenue multiple, and (1.2x) EV/EBITDA.
EV / Revenue (LTM)
4D Molecular Therapeutics Financial Valuation Multiples
As of March 21, 2026, 4D Molecular Therapeutics has market cap of $493M and EV of $210M.
Equity research analysts estimate 4D Molecular Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
4D Molecular Therapeutics has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $493M | XXX | $493M | XXX | XXX | XXX |
| EV (current) | $210M | XXX | $210M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 5687.7x | XXX | XXX | XXX |
| EV/EBITDA | (1.2x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | — | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (3.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 4D Molecular Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
4D Molecular Therapeutics Margins & Growth Rates
4D Molecular Therapeutics' revenue in the last 12 month declined by (83%).
4D Molecular Therapeutics' revenue per employee in the last FY averaged $0.3M.
4D Molecular Therapeutics' rule of 40 is (344%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
4D Molecular Therapeutics' rule of X is (468%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
4D Molecular Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (83%) | XXX | 230195% | XXX | XXX | XXX |
| EBITDA Margin | (261%) | XXX | (489557%) | XXX | XXX | XXX |
| EBITDA Growth | 57% | XXX | (15%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (344%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (468%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 125889% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 295% | XXX | 381889% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 507778% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
4D Molecular Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AIM Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| Synmosa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| GC Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Aquestive Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
4D Molecular Therapeutics M&A Activity
4D Molecular Therapeutics acquired XXX companies to date.
Last acquisition by 4D Molecular Therapeutics was on XXXXXXXX, XXXXX. 4D Molecular Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by 4D Molecular Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free Trial4D Molecular Therapeutics Investment Activity
4D Molecular Therapeutics invested in XXX companies to date.
4D Molecular Therapeutics made its latest investment on XXXXXXXX, XXXXX. 4D Molecular Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by 4D Molecular Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 4D Molecular Therapeutics
| When was 4D Molecular Therapeutics founded? | 4D Molecular Therapeutics was founded in 2015. |
| Where is 4D Molecular Therapeutics headquartered? | 4D Molecular Therapeutics is headquartered in United States. |
| How many employees does 4D Molecular Therapeutics have? | As of today, 4D Molecular Therapeutics has over 227 employees. |
| Who is the CEO of 4D Molecular Therapeutics? | 4D Molecular Therapeutics' CEO is David Kirn. |
| Is 4D Molecular Therapeutics publicly listed? | Yes, 4D Molecular Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of 4D Molecular Therapeutics? | 4D Molecular Therapeutics trades under FDMT ticker. |
| When did 4D Molecular Therapeutics go public? | 4D Molecular Therapeutics went public in 2020. |
| Who are competitors of 4D Molecular Therapeutics? | 4D Molecular Therapeutics main competitors are AIM Vaccine, Synmosa Biopharma, GC Biopharma, Aquestive Therapeutics. |
| What is the current market cap of 4D Molecular Therapeutics? | 4D Molecular Therapeutics' current market cap is $493M. |
| What is the current revenue of 4D Molecular Therapeutics? | 4D Molecular Therapeutics' last 12 months revenue is $69M. |
| What is the current revenue growth of 4D Molecular Therapeutics? | 4D Molecular Therapeutics revenue growth (NTM/LTM) is (83%). |
| What is the current EV/Revenue multiple of 4D Molecular Therapeutics? | Current revenue multiple of 4D Molecular Therapeutics is 3.1x. |
| Is 4D Molecular Therapeutics profitable? | No, 4D Molecular Therapeutics is not profitable. |
| What is the current EBITDA of 4D Molecular Therapeutics? | 4D Molecular Therapeutics has negative EBITDA and is not profitable. |
| What is 4D Molecular Therapeutics' EBITDA margin? | 4D Molecular Therapeutics' last 12 months EBITDA margin is (261%). |
| What is the current EV/EBITDA multiple of 4D Molecular Therapeutics? | Current EBITDA multiple of 4D Molecular Therapeutics is (1.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.